In particular, MeSeCys exhibited the potential to normalize angiogenesis and downregulate tumor-related proteins (such as androgen receptor and estrogen receptor α), thus overcoming tumor resistance to various therapeutic approaches, including chemotherapy 70, targeted therapy 71, and androgen deprivation therapy 69 (Table 1). This evidence concerns the gene ESR1 and neoplasm.